Cited by

• Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.

  Painter GR, Almond MR, Trost LC, Lampert BM, Neyts J, De Clercq E, Korba BE, Aldern KA, Beadle JR, Hostetler KY. Painter GR, et al. Antimicrob Agents Chemother. 2007 Oct;51(10):3505-9. doi: 10.1128/AAC.00460-07. Epub 2007 Jul 23. Antimicrob Agents Chemother. 2007. PMID: 17646420 Free PMC article.
• Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.

  Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Delaney WE 4th, et al. Antimicrob Agents Chemother. 2006 Jul;50(7):2471-7. doi: 10.1128/AAC.00138-06. Antimicrob Agents Chemother. 2006. PMID: 16801428 Free PMC article.
• HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007).

  Kalkeri R, Peng J, Huang C, Cai Z, Ptak RG, Suto MJ. Kalkeri R, et al. Adv Virol. 2020 Oct 14;2020:8844061. doi: 10.1155/2020/8844061. eCollection 2020. Adv Virol. 2020. PMID: 33110426 Free PMC article.
• Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids.

  Campagna MR, Liu F, Mao R, Mills C, Cai D, Guo F, Zhao X, Ye H, Cuconati A, Guo H, Chang J, Xu X, Block TM, Guo JT. Campagna MR, et al. J Virol. 2013 Jun;87(12):6931-42. doi: 10.1128/JVI.00582-13. Epub 2013 Apr 10. J Virol. 2013. PMID: 23576513 Free PMC article.
• High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay.

  Jansen RW, Johnson LC, Averett DR. Jansen RW, et al. Antimicrob Agents Chemother. 1993 Mar;37(3):441-7. doi: 10.1128/AAC.37.3.441. Antimicrob Agents Chemother. 1993. PMID: 8384813 Free PMC article.